Full Fed. Circ. Skips Biogen Fight Over MS Drug Patent
By Dani Kass (June 24, 2020, 10:15 PM EDT) -- Biogen lost another bid on Wednesday to ward off competition for its blockbuster multiple sclerosis drug Tecfidera, as the full Federal Circuit said it wouldn't reconsider a panel decision that Banner Life Sciences wasn't infringing a patent covering the drug.
Biogen International GmbH had been fighting the panel's April decision that a patent term extension granted to compensate for delays in the drug approval process was limited to a specific active ingredient. That meant Banner's drug, which involved a related ingredient, wasn't covered by the patent's extended life.
The May rehearing petition, which garnered support from the Pharmaceutical Research and Manufacturers of America, accused...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!